Director/PDMR Shareholding
Summary by AI BETAClose X
Morgan Sindall Group plc (the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
The following notification is intended to satisfy the Company's obligations under Article 19.3 of EU Regulation No 596/2014 (the Market Abuse Regulation).
|
1. |
Details of Restricted Person/person closely associated with them ("PCA") |
||||||||||
|
a) |
Name |
John Morgan (Chief Executive) |
|||||||||
|
2. |
Reason for the notification |
||||||||||
|
a) |
Position/status |
Chief Executive |
|||||||||
|
b) |
Initial notification/amendment |
Initial notification |
|||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a) |
Name |
Morgan Sindall Group plc |
|||||||||
|
b) |
LEI |
2138008339ULDGZRB345 |
|||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 5 pence each
ISIN: GB0008085614 |
|||||||||
|
b) |
Nature of the transaction |
Vesting of nil cost share options granted on 3 March 2023, under the Company's Deferred Bonus Plan, adopted by the Company on 28 November 2017. Upon vesting of the deferred bonus plan award on 3 March 2026, each nil cost option granted carried a right to receive an amount linked to dividends paid. The dividend equivalent has been settled in Ordinary shares of the Company and has been added to the original award of nil cost options.
The options and dividend equivalent shares are exercisable until the tenth anniversary of the grant date. |
|||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||
|
d) |
Aggregated information - Aggregated volume - Price |
As above
|
|||||||||
|
e) |
Date of the transaction |
3 March 2026 |
|||||||||
|
f) |
Place of the transaction |
Outside a trading venue |
|||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 19 minutes ago JPMorgan Emerging Markets Growth & Income plc
- 21 minutes ago National Grid
- 57 minutes ago City of London Investment Group
- 1 hour ago BioPharma Credit
- 1 hour ago BioPharma Credit